Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 460

Sort by

Sort Order Select

Journal Articles

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia

Yi Gong, Xinhua Zhang, Qianqian Zhang, Yanxia Zhang, Yuhua Ye, Wenxia Yu, Congwen Shao, Tizhen Yan, Jin Huang, Jianmei Zhong, Li Wang, Yaoyun Li, Liren Wang, Xiangmin Xu

Blood (2021) 137 (12): 1652–1657.

https://doi.org/10.1182/blood.2020006425

Published: 2021

Includes: Supplemental data

Journal Articles

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Alireza Paikari, MD, Ankush Goyal, MA, Celeste K. Kanne, BA, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 971.

https://doi.org/10.1182/blood-2019-131214

Published: 2019

Journal Articles

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Benjamin G Barwick, PhD, Sheri Skerget, PhD, Jonathan J Keats, PhD, Daniel Auclair, Sagar Lonial, Lawrence H. Boise, PhD, Paula M Vertino, PhD, Doris R Powell, MA

Blood (2019) 134 (Supplement_1): 858.

https://doi.org/10.1182/blood-2019-124422

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

Cell-Extrinsic Stressors from the Aging Bone Marrow (BM) Microenvironment Promote Dnmt3a -Mutant Clonal Hematopoiesis

Jennifer Myers SanMiguel, PhD, Matthew Loberg, BA, Sarah Heuer, Tim Stearns, Kira Young, PhD, Jennifer Trowbridge, PhD

Blood (2019) 134 (Supplement_1): 5.

https://doi.org/10.1182/blood-2019-124511

Published: 2019

Journal Articles

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Xiaochang Liu, PhD, Jiuxia Pang, Christopher Seiler, Ryan Kempen, Hao Liu, Aref Al-Kali, MD, Y. Natalia Tretyakova, Mark Litzow, MD, Shujun Liu

Blood (2019) 134 (Supplement_1): 2513.

https://doi.org/10.1182/blood-2019-130490

Published: 2019

Journal Articles

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Fatma Bulushi, Rahma Al-Riyami, MD, Zainab Al Hosni, MD, Bushra Al-Abri, Murtadha Al-Khabori, MD

Blood (2019) 134 (Supplement_1): 2604.

https://doi.org/10.1182/blood-2019-128402

Published: 2019

Journal Articles

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

Emily A Saunderson, PhDBSc, Kevin Rouault-Pierre, PhDBSc, John G. Gribben, MD DSc, Gabriella Ficz, PhDBSc

Blood (2019) 134 (Supplement_1): 2517.

https://doi.org/10.1182/blood-2019-130267

Published: 2019

Journal Articles

Single Cell Profiling of DNMT3A-Mutant Progenitors Reveals LY86 As a Novel Pre-Leukemia Marker and Potential Therapeutic Target

Mira Jeong, PhD, Sangbae Kim, PhD, Yumei Li, PhD, Rui Chen, PhD, Premal Lulla, MBBS, Margaret Goodell, PhD

Blood (2019) 134 (Supplement_1): 2724.

https://doi.org/10.1182/blood-2019-123597

Published: 2019

Journal Articles

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, MS, Daniil E Shabashvili, PhD, Jianping Li, MD, Luisa M Posada, Richard Lynn Bennett, PhD, Yang Feng, MS, Daphne Dupere Richer, PhD, Alberto Riva, PhD, Santhi Pondugula, PhD, Jonathan E. Bird, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2019) 134 (Supplement_1): 535.

https://doi.org/10.1182/blood-2019-128213

Published: 2019

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

Journal Articles

DNMT3A R882 Alters the Epigenome of Hematopoietic Cells

Amanda M Smith, PhD, Taylor LaValle, BS, Shamika Ketkar, PhD, Sai Mukund Ramakrishnan, MS, Christopher A Miller, PhD, Timothy J Ley, MD

Blood (2019) 134 (Supplement_1): 112.

https://doi.org/10.1182/blood-2019-129003

Published: 2019

Journal Articles

Tumor Suppressor Function of Dnmt3b in Hematologic Malignancies Critically Depends on Its Catalytic Activity

Katarina Lopusna, PhD, Pawel Nowialis, PhD, Staci L. Haney, PhD, Ajay Abraham, PhD, Jana Opavska, Rene Opavsky, PhD

Blood (2019) 134 (Supplement_1): 3788.

https://doi.org/10.1182/blood-2019-130857

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

Edurne San Jose, Naroa Gimenez-Camino, Obdulia Rabal, Estibaliz Miranda, Leire Garate, Fernando Garcia, Ana Alfonso Pierola, MD PhD, Sara Villar, Jose J. Rifon Roca, MD, Antonio Pineda-Lucena, Bruno Paiva, PhD, Javier Muñoz, Jesús San-Miguel, Julen Oyarzabal, PhD, Xabier Agirre, PhD, Felipe Prósper, MD PhD

Blood (2019) 134 (Supplement_1): 3762.

https://doi.org/10.1182/blood-2019-125578

Published: 2019

Journal Articles

The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study

Li Yang, Ligen Liu, Limin Zhao, Yingting Lu, Jing Zhang, Lihua Sun

Blood (2019) 134 (Supplement_1): 5108.

https://doi.org/10.1182/blood-2019-131671

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

NARROW

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Cell-Extrinsic Stressors from the Aging Bone Marrow (BM) Microenvironment Promote Dnmt3a -Mutant Clonal Hematopoiesis

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

Single Cell Profiling of DNMT3A-Mutant Progenitors Reveals LY86 As a Novel Pre-Leukemia Marker and Potential Therapeutic Target

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

DNMT3A R882 Alters the Epigenome of Hematopoietic Cells

Tumor Suppressor Function of Dnmt3b in Hematologic Malignancies Critically Depends on Its Catalytic Activity

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only